Arantza Muriana

Biobide takes part in a research about Malaria funded by Melinda and Bill Gates

Biobide (Bionaturis Group) has recently participated in a drug discovery research against malaria, a disease that causes about 440,000 deaths each year worldwide. The collaborative international project supported by Melinda and Bill Gates has the main goal of going from Hits to Leads among a selection of 400 compounds –included in the Malaria Box- to which researchers from 30 different countries have had access in the lastest two years. The final end is public institutions and the industry sharing more open knowledge in order to progress in new joint developments.

The promising results have just been published in a scientific paper and include the toxicity assays in zebrafish performed by Biobide to test the potential toxicity of the candidates to fight malaria. “Our presence in this study shows the versatility and usefulness of the zebrafish as animal model for drug discovery, as well as our expertise in this field. In addition to the obvious scientific value, this collaborative project has also a very relevant social value for Biobide, that is contributing in this way to find solutions for a disease that affected 95 countries worldwide in 2015”, the R&D Management Director at Biobide, Arantza Muriana, has stated.

In the 290 assays made by the different researchers for this study, 130 compounds have shown potential action against malaria which paves the way for a future election of the most suitable ones to develop new drugs. Additionally, some of these compounds have also shown outstanding activity against other disease agents, including bacteria, fungi, other parasites and even human cancer cells. In fact, these positive results have ignited over 30 drug development program devoted to fight different diseases. This initiative has been so satisfying that promoters are already repeating […]

August 2nd, 2016|Blog english|Comments Off|

Biobide strengthens its participation in international events

The schedule of Biobide scientists this spring is taken by very relevant international events in the sector. This week, the company acquired by Bionaturis Group and specialized in the use of zebrafish as animal model, presents two scientific posters in the Society of Environmental Toxicology and Chemistry (SETAC) Europe 26th Annual Meeting, 22-26 May 2016, at La Cite in Nantes, France.  Biobide also participates in the conference Measuring Behaviour 2016, hold in Dublin, with the research about the relationship between stress and exposure to light in this animal model.

R&D Management Director at Biobide, Arantza Muriana, will lead the presentation in SETAC 2016 of the posters titled ‘Testing toxicity of graphene oxide in zebrafish embryos’ and ‘Toxicity Profiling of Flame Retardants in Zebrafish’, both using zebrafish as animal model for varied toxicity and efficacy assays. The first one addresses the study of toxicity of graphene oxide, a very common material to produce goods used in our daily life, while the second one tackles the study of teratogenicity (possibilities of malformation in the development of the fetus in pregnant women), cardiotoxicity, hepatotoxicity and behavioral alterations in some flame retardants compounds found in everyday household products, to which people are regularly exposed. 

In addition to the presentation of these posters, Arantza Muriana and the Study Director, Virginia Caballero, will respond the large number of applications for one-to-one meetings in this event, considered the most important one in this specialized area in Europe. More than 2,000 scientists from 60 different countries will attend this event addressing relevant topics such as the climate change and contaminants or the production of cosmetics, among others.

Behaviour analysis

At the same time, Biobide takes part this week in the conference Measuring Behaviour 2016, considered the main […]

May 25th, 2016|Blog english, congress|Comments Off|

Biobide coordinates a course on zebrafish in the international annual conference of the Society of Toxicology (SOT) in New Orleans

Biobide (part of Bionaturis Group) participates in the most relevant scientific event devoted to toxicology and toxicity in the world, SOT and TOX Expo, held from 13rd March in New Orleans (USA). The participation of the company, which has grown in the latest meetings, includes the coordination of a course on zebrafish, the display of two scientific posters and the presence in the exhibition area with their own booth (number #1128).
The R&D Management Director at Biobide, Arantza Muriana, along with Mamta Behl from the NIH-NIEHS, is in charge of coordinating the course titled ‘Zebrafish As a Tool in Toxicology and Drug Discovery Screening’, held on March 13rd. The academic program, in which six experts will take part, aims to provide insight on the current developments in the use of zebrafish in the field of toxicology and drug safety and efficacy assessment, highlighting some ongoing challenges in the field. Specifically, Arantza Muriana will teach the chapter devoted to ‘Innovative Zebrafish Hepatotoxicity, Cardiotoxicity, and Neurobehavioral Toxicity Assays for Drug Selection”.
In addition to this course, Celia Quevedo, Study Director of Biobide will present on the 16th of March two scientific posters -number #1927 and #3299- with the collaboration of the company Stemina and the NIH-NIEHS, respectively. Both posters, which are included in the section titled Developmental Toxicology (Non Rodent)’, address the versatility of zebrafish to analyze toxicity, safety and efficacy of compounds.
“Our outstanding participation in such a relevant international congress as the SOT shows our expertise and confirms our position as partners of choice in the zebrafish sector worldwide”, Arantza Muriana has stated. Some months ago, Biobide set up a subsidiary in the USA, in the State of Maryland, and, recently they have signed a contract with […]

March 10th, 2016|Blog english, congress|Comments Off|

Arantza Muriana, honored with the prize Business Manager of the Year in Guipuzcoa by Aspegi Asociation

R&D Management Director and co-founder of BBD BioPhenix-Biobide (part of Bionaturis Group), Arantza Muriana, has been honoured with the prize Business Manager of the Year in Guipuzcoa by the Professional and Business Women Association from Guipuzcoa, Aspegi (in Spanish).  
The ceremony to collect the awards, whose winners have just been published, will be hold on the 10th of March at the Aquarium of San Sebastian. Among the winners in this first edition, Ana Belén Juaristi, General Manager of Engranajes Juaristi, who has been honored within the category Business Woman of the Year as well. With these awards, Aspegi aims to recognize the role of women in business, making more visible their significant contribution to the economic development in the area.

Bachelor of Pharmacy, Master degree in R+D+i of New Drugs and MBA, Arantza Muriana started working one decade ago in the field of Clinical Trials and, after a stay in the Salk Institute in California studying the zebrafish in the Preclinical Area, she came back to the Basque Country to join Biobide in its first stage. Nowadays, she is one of the co-founders of the company and the R&D Management Director, a relevant position that includes, among others tasks, management of the company’s R&D, the intermediation with pharmaceutical, biotechnology and chemical companies, or attendance at international events in the sector to present their innovations.
Biobide, an international reference company using zebrafish as animal model, offers tailor made solutions to customers all over the world to maximize R+D productivity and minimize risks in the Drug Discovery process, helping on the selection of more successful drug candidates (safer and more efficient). The latest milestones achieved by Biobide have been the foundation of a subsidiary in USA and the […]

March 7th, 2016|Blog english|Comments Off|

Bionaturis Group takes part in the North America SETAC Meeting, in Utah

Delegates of Bionaturis Group are attending this week the North American Meeting of the Environmental Toxicology Society (SETAC), held in Salt Lake City (Utah). This international event gathers more than 1,900 scientists, assessors, regulators and managers from 40 different countries to analyze the new issues in the sector through more than 1,600 presentations in only a week.

November 5th, 2015|Blog english, congress|Comments Off|

BBD BioPhenix shows the advantages of zebrafish in the SOT 2015 Annual Meeting and TOX Expo

Arantza Muriana, R&D Management Director at BBD BioPhenix (Bionaturis Group), is the delegate in the SOT 2015 Annual Meeting and TOX Expo hold from 22nd March in San Diego (USA). BBD BioPhenix –an international reference company in drug screening and the use of zebrafish as animal model in efficacy and toxicity assays for pharmaceutical, biotechnological, chemical and cosmetic sectors, among others- is one of the 350 companies in the world attending this international event that every year receives more than 6.500 attendees.

Besides its presence in exhibition and partnering zones, BBD BioPhenix will present a scientific poster titled ‘Screening of New Compounds That Alter Sleep-Wake State Alteration in Zebrafish’, which describes trials done with some anxiolytic drugs to analize how they can alter Sleep-Wake States in humans, through the Behavior alterations´ assay in zebrafish.

“Attending to this event is very relevant to consolidate our international customers and establish new high-level contacts that let us growing more and more”, Arantza Muriana has stated. The versatility of zebrafish and the drug screening automated processes in BBD BioPhenix provide a better selection of candidates, decreasing time and cost in the new active compounds discovery.

For further information about the SOT 2015 Annual Meeting, organized by the Society of Toxicology, please click here

March 16th, 2015|Blog english, congress|Comments Off|

“BioSpain 2014 has confirmed our position in the sector”

The delegates of Bionaturis Group at BioSpain 2014 has confirmed its positioning in the sector. In just three days they hold 40 one-to-one meetings to bolster existing business relationships and starting new collaborations for the next future.

“The quality and fruitfully meetings hold there demonstrate that we are in the right path. There are more and more multinational companies and institutions that are interested in working with us to move forward innovative solutions to the market. The unique features of the FLYLIFE platform to develop biological drugs and the versatility of the zebrafish animal model to optimize the drug discovery process were the hot topics during the meetings. A perfect blend between innovation and international expansion with a newborn effective presence in China makes us a perfect partner of choice”, the delegates have stated.

BBD BioPhenix presentation

Besides taking part as expositor within the Bionaturis Group stand (booth B9), BBD BioPhenix  gave a speech as part of the workshop titled “Key Enabling Technologies Applied to BIO”. In particular, R&D Manager, Arantza Muriana, delivered the conference “Key Enabling Technologies, fundamental part of zebrafish based screenings”.

In total, more than 3,000 partnering meetings has been hold in this forum and the presence of national and international investors has gained special relevance this edition. Check the highlights at #BioSpain2014.

 

 

September 30th, 2014|Blog english, Press english|Comments Off|

Bionaturis Group, at BioSpain 2014

Bionaturis Group is taking part this week in BioSpain 2014, the most important forum of this sector in Spain, that is being held in Santiago de Compostela. Bionaturis’ CSO, Juan Jose Infante, and BBD BioPhenix’s R&D Manager, Arantza Muriana, are the delegates of the companies in our stand (B9).

During these three days Bionaturis Group is meeting many high-level professionals. More and more institutions are relying on FLYLIFE special features and the versatility of the zebrafish, and so the activity of the delegates is intensive.

If you want to know more about BioSpain 2014, please click here
Follow the event in Twitter at #BioSpain2014

September 26th, 2014|Blog english, congress|Comments Off|

BBD BioPhenix diversifies Biotechnology application

One of the current challenges of BBD BioPhenix (acquired by Bionaturis) is gaining position in other markets different from pharmaceutical or veterinarian ones. The versatility of its services and the high capability of its  facilities to the tailor made requirements of its customers  make BBD an essential partner in drug discovery research for other sectors such as agrochemical, petrochemical, cosmetics and nutraceutical.

“We are already working in interesting projects outside the pharmaceutical arena thanks to the suitable features of the zebra fish model for active ingredients screening and our intention is going on this track”, R&D manager Arantza Muriana, states. BBD has a zebrafish facility able to grow up to 20,000 adults, including different lines that allow developing general and organ-specific toxicity and efficacy assays. In its lab, BBD is capable of developing biological and molecular assays under robust automatization processes.

“Nowadays, biotechnology can be applied to very different sectors and its more and more presence in our daily life”, the manager adds.

In case of BBD, the regulatory framework of the main markets is becoming an ally. Besides including the use of the zebrafish as a model in the guidelines for toxicity assays in chemical, agrochemical and cosmetic products, the limitations in the use of animals models for experimental assays are increasing (in accordance to the 3-R’s Rules: Replacement, Reducement and Refinement). These new guidelines do not exclude the use of zebrafish, because it is not considered as a superior animal model in these situations as long as the assays are made with embryos aged up to five days old. In this way, the use of the zebrafish model is becoming one of the alternatives with more applications.

Find below some of the OECD Guidelines including zebrafish as an […]

September 5th, 2014|Blog english|Comments Off|

Bionaturis Group enhances its international alliances in San Diego (USA)

Bionaturis and BBD Biophenix have taken part in the latest edition of Bio International Convention 2014, in San Diego (June 2014), where the hard-working days have strengthened the international strategies and alliances of the group.

Along three days, the delegates moved to San Diego, Juan Jose Infante (Bionaturis) and Arantza Muriana (BBD Biophenix), has had up to 60 high-level ‘One to One’ meetings, mixing follow-up meetings with already pharmaceutical and veterinarian clients with the evaluation of development opportunities with new ones. The managers of both companies in the Convention have stated: “They have been more than fruitful meetings to consolidate our relationships with current and future partners and to confirm how our join innovative portfolio is at the forefront of the industry, so that we expect to sign new contracts shortly”.

In particular, Bionaturis´ attention has been focused on its portfolio of biological products and the unique features of its FLYLIFE platform as well, whereas BBD has validated the relevance of zebra fish as animal model for increasing the screening success rate not only for the pharmaceutical sector but also for petrochemical, agrochemical, nutraceutical and cosmetics ones.

The Convention in San Diego has also provided a great opportunity to go further within the global expansion plan, with M&As and international growth in Asia and LATAM as  cornerstones.

Expositor

This year Bionaturis Group has participated as exhibitor within the Spanish pavilion, having a booth sponsored by Biobasque. The dynamism shown in this Convention and the record number of partnering meetings is a prove of a wealthy sector with high potential growth. The event showcased the official presentation of Bionaturis Group, after the recent acquisition of BBD Biophenix.

July 4th, 2014|Blog english, Press english|Comments Off|

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.

CERRAR